Peppermint Oil: IBS Trial Results, Safety and Funding

Key takeaways

  • Enteric-coated peppermint oil has a short-term IBS symptom signal in pooled trials, but the 2022 review rated certainty very low and newer trials have not consistently confirmed it
  • A fully verified independent-only effect estimate is unavailable; these findings do not establish a dependable benefit for every retail product
  • Peppermint oil, peppermint tea, isolated menthol and peppermint–caraway combinations have different evidence
  • Reflux and heartburn can worsen. An enteric coating reduces early release; it does not guarantee freedom from side effects
  • A large 2026 pediatric trial found no advantage over its comparator. Adult results should not be turned into a children's self-treatment recommendation

Peppermint oil has mixed short-term IBS results. The 2022 adult synthesis reported pooled symptom relief with very low certainty; its low-bias global-symptom subgroup was inconclusive, while its pain subgroup remained positive with wide uncertainty. Modern adult trials missed primary endpoints, and a 2026 pediatric trial found no superiority. Known commercial ties and unreported supply terms prevent a fully verified independent-only estimate. Reflux can worsen; the reviewed human studies do not establish gut-healing or antimicrobial treatment. Adult review, US trial, Dutch trial, Pediatric trial, Safety guidance

Contents

Evidence summary · What it is · Selected formulations · Mechanism · Hype · Benefits · Verdicts · Risks · Interactions · Who should avoid · Studied doses · Laboratory evidence · Funding · Regulation · FAQs · Sources

Evidence summary

Favorable trial results and financial independence are separate questions. Commercially supported trials are retained as clinical context, including null findings. Some full reports or procurement terms remain unavailable, so this review cannot calculate a fully verified independent-only pooled benefit. Missing information remains unknown. Review, US trial, PERSUADE, Pediatric trial

ClaimEvidenceSourceFunding/conflictStrength
Relieves adult IBS symptomsPooled benefit, with very low certainty and more adverse eventsIngrosso 2022, accepted manuscriptAccepted main paper recovered; no separate review financial declaration found in that version; mixed underlying provenancePossible benefit; insufficient independent estimate
Improves IBS compared with placebo in a modern US trialNo significant primary or secondary advantageNee 2021NIH funding verified; full final disclosure and procurement terms unresolvedImportant null trial; not proof of universal inefficacy
Improves modern IBS responder endpointsBoth tested release formulations missed primary endpoints; some small-intestinal-release secondary results favored oilWeerts 2020Public grant plus explicit in-kind capsules, commercial collaboration and licensing interestsKnown commercial ties; not independent-only corroboration
Helps children with IBS or functional abdominal painNo superiority in a 228-child trialVermeijden 2026Charity support; manufacturer provision with payment terms unknown; indirect author tiesDoes not establish pediatric benefit
Treats functional dyspepsia by itselfCombination research cannot isolate peppermint oilChey 2019IM HealthScience funding and author tiesInsufficient for oil alone
Raises some medicine exposureSmall human felodipine experiment; cyclosporine finding is from ratsDresser 2002; Wacher 2002AvMax affiliations; complete financing unresolvedLimited interaction signal, not a universal drug-interaction rule

What it is

Peppermint, Mentha × piperita, is a hybrid of water mint and spearmint. Its essential oil is a concentrated preparation obtained from the plant's aerial material, including leaves and flowering parts. Menthol is an important constituent, but the oil contains multiple compounds. Leaf tea, an oil capsule and isolated menthol are not dose-equivalent preparations. NCCIH ingredient overview

This article concerns swallowed preparations and digestive claims. Aromatherapy for nausea, topical treatment, dental products and clinician-administered endoscopic preparations require separate evidence. A procedural antispasmodic effect cannot establish that a retail capsule improves a chronic digestive disorder.

Selected formulations

FormImportant distinctionWhat to check
Gastro-resistant or enteric-coated capsulesCoating delays exposure until after the stomachExact release system, amount per capsule and instructions
Small-intestinal-release microspheresA proprietary delivery system can differ from a conventional capsuleEvidence for that complete formulation
Ileocolonic-release capsulesIntended delivery farther down the bowelThis formulation did not outperform placebo on the main endpoints in Weerts' trial
Uncoated oil or essential-oil dropsConcentrated oil can contact the mouth, oesophagus and stomach directlyDo not improvise an oral dose from an aromatherapy bottle
Peppermint tea or leaf extractDifferent composition and exposureCapsule findings do not establish equivalent effectiveness
Isolated menthol or peppermint plus carawayAnother molecule or a combination interventionAttribute findings to the studied intervention

Release location is part of the treatment, not a cosmetic feature. “Natural,” “ultrapurified” or “clinical strength” does not show independent clinical superiority. The examined products include a UK-authorized 0.2 mL capsule and proprietary US supplements; regulatory status and excipients differ. Colpermin product information, IBgard manufacturer page

How it works

The central rationale is relaxation of gastrointestinal smooth muscle. Laboratory pharmacology implicates calcium-dependent contraction, while menthol-sensitive sensory pathways are also being investigated. Enteric coatings aim to deliver the oil farther down the digestive tract. These mechanisms make an antispasmodic effect plausible; they do not tell us the size or durability of pain relief in everyday IBS. NHS mechanism explanation, regulated product pharmacology

IBS symptoms fluctuate, and participants can improve with reassurance, follow-up, background treatment or placebo. Consequently, a before-and-after improvement is less informative than the difference from a well-matched control. The NIH-supported peppermint study was nested within a placebo-research program, making that distinction particularly relevant. Ballou protocol

Hype versus evidence

The reasonable claim is limited symptom relief in a defined setting. Claims that peppermint repairs the intestinal barrier, eliminates SIBO, restores a microbiome, treats inflammatory bowel disease or cures every kind of bloating go beyond the human outcomes reviewed here. Laboratory antimicrobial activity would not establish eradication of a diagnosed infection, and pain relief would not demonstrate mucosal healing.

The American College of Gastroenterology's 2021 guideline conditionally suggested peppermint for global IBS symptoms using low-quality evidence. That is a treatment option within clinical care, not a guarantee of benefit or a finding that all underlying studies were commercially independent. ACG guideline

A manufacturer currently promotes targeted delivery and rapid abdominal comfort. Those statements identify what is being marketed; they do not supply independent corroboration. Manufacturer's claim

Benefits by claim

Adult IBS pain and global symptoms Insufficient independent evidence

The 2022 synthesis included 10 adult randomized trials and 1,030 participants. Failure-to-improve relative risks were 0.65 (95% CI 0.43–0.98) for global symptoms and 0.76 (0.62–0.93) for pain. The global-symptom NNT was 4 with a wide 2.5–71 interval. Among low-risk-of-bias studies, global improvement was inconclusive (two trials, 261 participants; RR 0.77, 0.28–2.08), while pain remained positive but imprecise (three trials, 351 participants; RR 0.78, 0.61–0.99). Heterogeneity, publication-bias concerns and imputed pain-response counts limit the estimates; the authors rated certainty very low. Commercially linked trials are included, so this is not an independent-only effect estimate. Ingrosso 2022, accepted original manuscript

Nee’s US trial tested 180 mg three times daily for six weeks. Mean symptom-severity improvement was 90.8 points with peppermint and 100.3 with placebo, with no significant between-group difference; reported secondary comparisons were also null. NIH financing is documented. The related prospective protocol describes 0.2 mL Pepogest softgels and a manufactured soybean-oil placebo, without purchase or donation terms. The completed paper’s full methods and financial declarations remain unrecovered. Public grant support therefore does not fully resolve provenance or establish universal ineffectiveness. Nee 2021, prospective protocol, NIH award

The Dutch PERSUADE trial found no significant advantage on either prespecified pain-responder or overall-relief endpoint after eight weeks. Some exploratory small-intestinal-release pain, discomfort and severity comparisons favored oil; this was not consistent across measures or visits, and the trial used stricter multiplicity thresholds. Six-month follow-up after stopping treatment did not show significant group differences. Will Pharma supplied capsules in kind, collaborated on the study and held relevant commercial agreements; author and employer licensing relationships were disclosed. Public grant support does not remove those ties. Weerts 2020, published original with tables and disclosures

Cash’s four-week trial involved 72 adults with diarrhea-predominant or mixed IBS and a targeted-delivery preparation. Its primary symptom-score improvement was 40% with oil versus 24.3% with placebo (p = 0.0246). The short study used restricted background/rescue treatments and last-observation carry-forward; it does not establish every IBS subtype or long-term benefit. IM HealthScience funded it, and the authors included a company consultant and medical/innovation officers. These are formulation-specific findings with direct commercial ties. Cash 2016

Children's IBS and functional abdominal pain Insufficient

In the 2026 multicenter Dutch trial, 228 children aged 8–18 were randomized to peppermint-oil capsules, peppermint sweets or comparator capsules. Treatment success was 44.0% with oil and 37.3% with comparator, a nonsignificant difference; sweets also showed no advantage. Adequate relief did not differ significantly. The comparator contained a small amount of peppermint oil for blinding, so it was not chemically oil-free. The funding statement names SPIN/Cultuurfonds support and products provided by Will Pharma and Fortuin; payment terms are not specified. Keszthelyi disclosed earlier Will Pharma co-funding, and Benninga disclosed several company consultancies. These findings do not justify routine pediatric self-treatment. Vermeijden 2026

Functional dyspepsia and upper abdominal discomfort Insufficient for oil alone

The 2019 FDREST trial tested duodenal-release caraway oil plus L-menthol, rather than peppermint oil alone. In 95 analyzed adults, a 24-hour postprandial-distress comparison favored the combination, but overall global improvement at two and four weeks and the four-week clinical global comparison were not significant. Selected subgroup findings were exploratory and not adjusted for multiple comparisons. IM HealthScience funded the trial and several authors had company roles. This combination cannot isolate peppermint’s contribution or establish general dyspepsia benefit from oil alone. Chey 2019 FDREST

This distinction also matters clinically: indigestion, reflux and IBS are different symptom patterns. Peppermint can aggravate reflux even when it is being considered for lower-bowel cramps. NCCIH IBS guidance

Gut healing, SIBO eradication and long-term prevention Insufficient

The evidence assessed here does not establish these outcomes. A short symptom trial cannot show prevention of future disease or sustained benefit after discontinuation. This is an evidence boundary, not proof that every untested effect is impossible. Long-term effectiveness remains uncertain in public clinical guidance. NCCIH IBS evidence

What works and what does not

ClaimVerdictNotes
A short-term IBS treatment option for selected adultsPossible benefit, uncertain independent magnitudeConsistent enough for a conditional guideline suggestion; conflicting modern trials and funding gaps remain
A proven benefit from any peppermint productUnsupportedPreparation, population and endpoint differ
A reliably effective pediatric treatmentNot establishedRecent controlled results were null
A reflux remedyPoor fitCan worsen heartburn
Peppermint tea equals an enteric-coated capsuleUnsupported equivalenceNo matching exposure or delivery evidence
A microbiome reset or gut-lining repairNot establishedAppropriate clinical outcomes are missing

Risks and reported side effects

AspectFindingSource
Reflux and irritationHeartburn, indigestion and anal irritation can occurNHS safety
Aggregate trial adverse eventsAny adverse event RR 1.57 (95% CI 1.04–2.37) and reflux RR 1.67 (1.18–2.38) in the 2022 pooled trialsIngrosso 2022
AllergyPeppermint or another capsule ingredient may provoke a reactionNHS safety
Product-specific allergensThe examined UK Colpermin label lists peanut oil and cautions people with peanut or soya allergyColpermin label
Liver and biliary conditionsEMA's digestive-use summary excludes liver disease, gallstones, other bile-related problems and achlorhydriaEMA public summary
Pregnancy and breastfeedingData are limited; guidance differs in caution between products and institutionsNHS pregnancy page; product label

A 2025 case letter described liver-enzyme elevations during escalating use of two peppermint-containing products, improving after withdrawal. Its original report contains inconsistent dose descriptions and additional care alongside withdrawal. A single case cannot establish incidence, a safe dose ceiling or which ingredient caused the abnormalities. The authors reported no manuscript-preparation support or conflicts; an NIH grant is separately indexed, and detailed individual disclosures and supply terms remain unresolved. Ali 2025 original case, reported financial declarations, indexed NIH grant

Safety note: Breathing difficulty, sudden swelling of the mouth or throat, or collapse requires emergency care. Do not experiment with concentrated oil in response to persistent or unexplained abdominal symptoms. New bowel bleeding, persistent vomiting, weight loss or worsening symptoms needs medical assessment. This is a selection of relevant risks, not a complete adverse-event inventory. NHS emergency allergy guidance, NHS suitability guidance

Interactions and important gaps

Substance or conditionMechanism or concernSeverity/statusSource
Antacids, PPIs and H2 blockersAltered gastric conditions can interfere with intended releaseFormulation-specific caution; check the actual product and pharmacist's adviceNHS interaction guidance
FelodipineA 12-person experiment using 600 mg oil increased average drug exposure to 140% of the water condition, with wide individual variationHuman pharmacokinetic signal; clinical consequences and usual-capsule relevance uncertainDresser 2002
CyclosporineIncreased exposure in a rat experimentPreclinical warning, not a verified human interaction magnitude; specialist review is appropriateWacher 2002
Other medicines and herbal productsLaboratory metabolic effects do not establish every proposed clinical interactionComprehensive testing is absentNHS evidence gap
AlcoholMay worsen dizziness or other adverse effectsTolerability cautionNHS common questions
Existing reflux or hiatus herniaSymptoms may worsenA clinically relevant suitability issueNCCIH IBS guidance

NHS advice describes a two-hour gap from indigestion medicines. This does not prove that spacing neutralizes every effect of a long-acting acid suppressant or suits every release system. Check the full medicine list and particular capsule with a clinician or pharmacist; do not stop prescribed treatment to accommodate a supplement. NHS medicine guidance, Colpermin instructions

Who should avoid self-treatment

People with unexplained or alarm symptoms should first have the cause assessed. Reflux, gallbladder or liver disease, low stomach acid, pregnancy, breastfeeding and relevant allergies warrant individual review. The EMA and individual labels have different age limits; a research protocol is not permission to dose a child. EMA digestive-use restrictions, NHS suitability

An existing IBS care plan should not be abandoned because evidence certainty or financial independence is limited. These judgments describe what the reviewed studies establish, rather than whether a particular person should discontinue prescribed care. Treatment choices should be discussed with the treating clinician. ACG conditional recommendation, NCCIH guidance

Dosage and how it was taken in research

These are study exposures, not dosing recommendations. Different coatings and units are not interchangeable.

Use caseStudied exposureDurationNotes
Adult IBS, US trial180 mg three times daily6 weeksNo superiority over placebo; Nee
Adult IBS, Dutch trial182 mg three times daily, two release designs; first-week titration8 weeksPrimary endpoints null; Weerts
Non-constipated adult IBS180 mg three times daily in a proprietary microsphere system4 weeksMaker-funded study; Cash
Pediatric IBS/functional painAge-dependent capsule or sweet protocol with potential escalation8 weeksNo proven advantage; not reproduced as home instructions; Vermeijden
Drug-interaction experiment600 mg oil with felodipineAcute crossoverNot a therapeutic digestive regimen; Dresser

Gastro-resistant capsules should be used according to their actual instructions rather than crushed or chewed. Oil released early can irritate the upper digestive tract. Colpermin handling instructions

Animal and in vitro evidence excluded from benefit conclusions

The cyclosporine experiment was conducted in rats and included AvMax-affiliated authors. It explains a repeated interaction concern without establishing a human exposure or harm rate. The human felodipine abstract also reports microsomal experiments and a tentative intestinal-metabolism explanation. Laboratory enzyme effects cannot establish a clinically important interaction with every medicine using that pathway; the full interaction-paper methods and financial disclosures remain unavailable. Rat cyclosporine study, Human felodipine study

No animal, cell-culture or isolated-tissue result establishes the IBS benefit grade in this article. Mechanistic plausibility and efficacy are assessed separately.

Funding and financial relationships

Follow the money

Research funding at a glance

Funding & backersSource & studyClaim & limits

28 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.

No single explicit tier could be mapped. This graphic does not assign a new tier or infer independence.

Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.

What the research money shows

The US programme has identifiable NIH cash financing and unresolved product-procurement terms. PERSUADE documents Will Pharma in-kind support and relevant author/employer agreements. Cash’s trial documents company financing and company-linked authors. The pediatric paper identifies company-provided products without specifying payment terms, alongside separately disclosed author relationships. These different relationships require source-specific interpretation; a public or charitable funder does not remove a commercial product or licensing stake. US protocol, PERSUADE disclosures, Cash disclosures, Pediatric disclosures

An arm's-length product purchase is not sponsorship. An undisclosed procurement arrangement remains unknown. Academic control over analysis is reassuring, but it does not erase manufacturer financing, donated products, commercial authorship or a relevant licensing stake. The same eligibility rule applies to favorable and unfavorable outcomes.

Companies, countries and backers

IM HealthScience was the US sponsor of Cash’s trial. Nestlé Health Science announced an agreement to acquire its business and brands in August 2020; Nestlé’s later report confirms closing in September 2020. IBgard is currently listed on the Nestlé Health Science website, whose corporate announcement identifies its global headquarters in Vevey, Switzerland. These later ownership records do not imply Nestlé financed the earlier trial. August agreement and company identity, September closing report, current IBgard page

Nestlé's 2025 governance report lists notified stakes of 5.04% for BlackRock, 5.547% for UBS Fund Management (Switzerland), and 3.006% for Capital Group. Those figures refer to notifications dated January 2022, May 2024 and January 2025 respectively, not a live October 2026 shareholder register. Investment-manager holdings do not establish control over a particular study. Ultimate fund clients and trial-level decision rights were not traced. Capital Group identifies its corporate headquarters in downtown Los Angeles, USA. 2025 report, significant shareholders; Capital Group headquarters disclosure

Will Pharma describes itself as a continuing family business with Dutch origins and Belgian operations. Its exact ultimate ownership percentages were not verified from primary filings. The business relationship to the Dutch trial is nevertheless explicit in the paper. Plant origin, oil-production country, capsule manufacturing country and a sponsor's headquarters should not be conflated. Will Pharma history

Documented money map

Documented funding and ownership relationships for peppermint oil. The full equivalent text and linked sources appear in the article.
Documented funding relationships and dated corporate notifications. Open the full-size map. The text below explains the verified relationships, source dates and remaining gaps.

Plain-text version:

  • NIH/NCCIH in the USA funded the US research program; product procurement remains unresolved
  • ZonMw in the Netherlands funded PERSUADE, while Will Pharma provided in-kind capsules and held relevant commercial agreements
  • US-based IM HealthScience funded the Cash trial and supplied company-linked authors
  • Nestlé confirms the IM HealthScience acquisition closed in September 2020; this does not retrospectively attribute the earlier trial to Nestlé. Closing report
  • Nestlé's report lists the dated BlackRock, UBS and Capital Group notifications above; these are corporate investments, not documented trial instructions

The trial literature spans several countries, while key product relationships in the modern studies are concentrated in US and Dutch/Belgian businesses. Nationality alone establishes neither reliability nor bias. Missing budgets, older trial disclosures and manufacturing details remain gaps. Funding is not proof of a false finding; it is relevant to the independence of corroboration.

Regulatory status

United Kingdom and European Union

The examined UK Colpermin product has a marketing authorization for IBS symptom relief. EMA’s assessment concerns specified peppermint-oil preparations; national authorities assess individual medicinal-product applications. This does not authorize every essential-oil bottle or provide an independent pooled treatment estimate. The March 2026 scientific-data call had a 15 March–15 June submission window, now marked closed; it is a review step rather than a new approval. UK label, EMA document record, original 2026 call

United States

A dietary supplement is not preapproved by FDA for safety and effectiveness in the way a drug is. Disease-treatment claims and general supplement marketing operate under different rules. A study, a trademark or an ingredient label should not be represented as FDA approval to treat IBS. FDA supplement questions

Frequently asked questions

Does peppermint oil work for IBS?

The 2022 adult pool suggested short-term relief with very low certainty, while the low-bias global and pain subsets differed. The 2021 guideline made a conditional suggestion, and modern adult primary-endpoint results were null. Known commercial ties and unresolved supply terms prevent a fully verified independent-only estimate or a dependable prediction for every product or person. Review, guideline, US trial, Dutch trial

Can I use peppermint tea instead?

Tea has a different composition and exposure. A preference for tea is not evidence that it reproduces a studied capsule's effect.

Why can something used for cramps worsen heartburn?

The intended lower-bowel effect does not make the same preparation suitable for the oesophagus or stomach. Reflux is a recognized adverse effect, including with some coated products.

Is the children's research positive?

The recent large Dutch comparison did not establish superiority. Its results and age-specific research protocols do not justify self-dosing children.

Does uncertain evidence mean my improvement is imaginary?

An individual’s improvement can be real while its cause remains uncertain. The review’s evidence and financial classifications describe study-level support, not a diagnosis of that person’s experience. Fluctuating symptoms, background care and the control-group comparison matter; financial uncertainty does not prove a study false. Placebo-programme protocol, controlled trial

Sources and funding notes

The tiers describe documented interests: 1 indicates no identified relevant stake in the available disclosures, 2 indirect ties, 3 an interested party, 4 direct commercial origin or support, and U unresolved financial provenance. These are provisional editorial classifications, not proof that every financial chain is known. Credibility A–D addresses the source’s role and accountability separately from study methods and formal GRADE certainty. Official guidance and corporate filings can document rules or ownership without proving the cited clinical trials independent.

SourceFunding, ownership and countryTier / credibilityAccuracy incentive and residual gap
Ingrosso 2022 review, accepted originalAccepted main paper recovered; no separate funding or COI declaration found in that version; final-publisher declarations and underlying finances unresolvedU / B provisionalMethods and full trial tables read; commercial underlying trials, very-low certainty and publication-bias concern
Nee 2021US academic trial; NIH award verified; complete main paper, final disclosures and procurement unresolvedU / B provisionalStructured abstract and public grant record read; no complete methods or financial clearance
Ballou 2017 protocolNIH/NCCIH grants, USA; no competing interests declared; commercial product sources named without payment termsU / B provisionalProspective methods; not a completed result or procurement invoice
NIH awardUS federal research agency1 / A for grant recordPublic accountability; cash award alone cannot exclude in-kind support
Weerts 2020Netherlands; ZonMw, Will Pharma in-kind products and relevant licensing agreements4 / CDetailed original outcomes and disclosures; null primaries and selected exploratory secondaries; known commercial ties
Cash 2016IM HealthScience, USA, funded study; consultant and company officers authored it4 / CControlled experiment; direct commercial stake
Vermeijden 2026Netherlands; SPIN supported by Cultuurfonds; Will Pharma/Fortuin procurement terms unknown; prior Will Pharma co-funding for Keszthelyi and Benninga company consultancies disclosed separatelyU / B provisional; indirect author tiesOriginal abstract and indexed support/COI read; complete main tables and product payment terms unavailable; no pediatric superiority
Chey 2019IM HealthScience financing and company roles, USA4 / CTrial methods; combination cannot isolate peppermint
Ali 2025 case report, disclosures, PubMed recordUS academic clinicians; no manuscript-preparation support or conflicts declared; NIDDK R01 DK123549 separately indexed; detailed forms and supply terms unresolvedU / B provisionalFull main case letter read; individual disclosure forms unrecovered; single case, multiple products and dose inconsistencies limit attribution
Dresser 2002Canadian university and US AvMax affiliations; complete funding, author disclosures and company ownership unresolvedCommercial affiliations / C provisionalOriginal abstract and affiliations read; 12-person pharmacokinetic signal; human mechanism tentative; full paper unavailable
Wacher 2002US AvMax affiliations; complete funding, author disclosures and company ownership unresolvedCommercial affiliations / C provisionalOriginal rat abstract read; vehicle matters; no verified human magnitude or full-main financial clearance
ACG 2021 guidelineUS professional society; no financial support reported; Chey discloses IM Health consulting and Moshiree Nestlé consulting3 / COriginal recommendation, methods and disclosures read; conditional low-quality advice; no independent-only trial pool
NCCIH peppermint overviewUS federal NIH center, public research mission1 / A for public guidanceNamed literature and accountability; summary is not a new trial
NCCIH IBS guidanceSame US public institution1 / A for guidanceExplains limits; does not certify underlying trial independence
NHS common questionsUK publicly funded health service1 / A for practical guidancePublic safety mandate; broad advice rather than a formulation trial
NHS side effectsUK public health service1 / ASafety accountability; cannot supply precise incidence for every product
NHS suitabilityUK public health service1 / ATriage and medicine-use guidance; individual assessment still needed
NHS pregnancy and breastfeedingUK public health service1 / APublic guidance; acknowledges limited data
NHS interactionsUK public health service1 / AExplicit knowledge gaps; timing advice is not a universal compatibility study
Colpermin SmPCMcNeil Products Limited, UK authorization holder; company-origin document hosted by emc; ultimate ownership unresolved4 / CRegulated label accountability; used for contents, instructions and warnings, not independent efficacy
EMA public summaryEU agency headquartered in Netherlands; public contributions and regulated-industry fees2 / A for regulatory scopeLegal mandate; assessment includes literature with commercial ties
EMA assessment recordSame EU agency2 / A for document statusDated adopted documents distinguished from consultation
EMA budget programEU/EFTA contribution and service-fee revenue in the 2026 budget forecast2 / A for institutional financeOfficial forecast tables read; not final receipts or evidence that a particular decision was purchased
FDA supplement guidanceUSA; official federal regulatory guidance; agency-wide budget and funding mix not established by this cited pageOfficial role / A for legal scope; financing unverifiedCurrent statutory Q&A read; used for supplement rules, not clinical efficacy or financial clearance
Nestlé acquisition agreement, complete announcement, closing reportSwiss corporate group, interested primary disclosure4 / CPrimary agreement, headquarters statement and September 2020 closing verified; promotional outcome claims excluded
IBgard corporate pageNestlé Health Science, Switzerland; product sales4 / D for marketing, C for identityCommercial incentive; used to establish brand connection and stated claims
Nestlé 2025 governance reportListed Swiss company; disclosed institutional investors4 / CFiling accountability; dated notifications, not real-time ownership
Will Pharma historyDutch/Belgian family-business self-description; exact stakes unverified4 / CPublic corporate identity; promotional account is not an ownership audit

Scope: selected digestive outcomes and safety sources. Full relevant originals were recovered for several trials and the adult synthesis, while some final papers, individual disclosure forms and supply terms remain unavailable. No complete independent-only trial census, product catalogue or interaction inventory is claimed.

Last reviewed: 1 October 2026.

Have a question — or want us to cover something?

Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.

We store your topic, message, optional email, and this page so we can manage and reply to the request. Do not include diagnoses, medications, or other sensitive medical information. See our Privacy Policy.